• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Anaptysbio Inc (NQ: ANAB )

    21.27 -1.44 (-6.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 267,275
    Open 22.56
    Bid (Size) 20.00 (1)
    Ask (Size) 34.30 (2)
    Prev. Close 22.71
    Today's Range 21.06 - 23.10
    52wk Range 13.36 - 27.50
    Shares Outstanding 27,433,359
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BTIG Research Predicts Over 118% Rally for These 3 Stocks
    Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money. 
    Via InvestorPlace
    Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
    A powerfully bullish new analyst take on the company helped it rally on the market. 
    Via The Motley Fool

    Performance

    YTD
    -1.98%
    -1.98%
    1 Month
    -8.20%
    -8.20%
    3 Month
    -4.49%
    -4.49%
    6 Month
    +14.97%
    +14.97%
    1 Year
    -5.76%
    -5.76%

    More News

    Read More
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Unveiling 4 Analyst Insights On AnaptysBio
    Via Benzinga
    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
    Via Benzinga
    Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Named a BioSpace 2024 Best Places to Work Winner
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Participation in November Investor Conferences
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Argenx's 28% Surge & Promising Product Propel Investor Confidence
    Via MarketBeat
    AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
    From AnaptysBio, Inc.
    Via GlobeNewswire
    AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.